Last reviewed · How we verify
NCT04696042: AIM-NETs
Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs
trial testing Lanreotide autogel in Neuroendocrine Tumors in 71 participants. Completed in 27 January 2025.
30 January 2024
Quick facts
| Lead sponsor | Asan Medical Center |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 71 |
| Start date | 1 January 2021 |
| Primary completion | 30 January 2024 |
| Estimated completion | 27 January 2025 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Lanreotide autogel
Conditions studied
- Neuroendocrine Tumors — all drugs for Neuroendocrine Tumors →
Sponsor
Asan Medical Center
Who can join
19 and older, any sex, with Neuroendocrine Tumors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Lanreotide Autogel® has been established as a standard of care for patients with locally advanced or metastatic GEP-NETs based on the success of CLARINET trial. However, only few patients with Asian ethnicity were included in the trial. According to the nationwide comprehensive study of patients with GEP-NET in Korea, hindgut primary NETs(Rectal) occured more frequently than western countries. However, small intestine or lung primary NET is relatively rare compared with western countries.1) Considering the clinical characteristics of GEP-NETs are distinct between the patients in Asian and Western countries, further evaluation on the efficacy and safety of Lanreotide Autogel® in Asian patients with GEP-NETs is needed.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
From biology to clinical practice: antiproliferative effects of somatostatin analogs in neuroendocrine neoplasms.
Melhorn P, Mazal P, Wolff L, Kretschmer-Chott E, et al · · 2024 · cited 3× · PMID 38529270 · DOI 10.1177/17588359241240316
Verify or expand the search:
- PubMed search for NCT04696042
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Lanreotide autogel
Trials testing the same drug.
- NCT06607666 — Acromegaly Resistant to Conventional Dose of First Generation Somatostatin Ligands · completed
- NCT04852679 — Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs · Phase 3 · completed
Other recruiting trials for Neuroendocrine Tumors
Currently open trials in the same condition.
- NCT07404176 — Study to Assess the Safety and Effectiveness of Novel Radiopharmaceutical Terbium-161 DOTATATE in Metastatic Neuroendocr · Phase 2 · recruiting
- NCT07314164 — Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment · recruiting
- NCT07272512 — Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms · Phase 4 · recruiting
- NCT06735560 — Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NEN · NA · recruiting
- NCT06889493 — SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Dif · Phase 1 · recruiting
Other Asan Medical Center trials
Trials by the same sponsor.
- NCT07530393 — Blood Viscosity and Outcomes After Elective Craniotomy · not yet recruiting
- NCT07010497 — A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Be · Phase 2 · recruiting
- NCT07382505 — Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cerv · not yet recruiting
- NCT07489092 — Feasibility of a Digital Rehabilitation Platform in Patients After ICU Discharge · NA · recruiting
- NCT07431762 — Comparison of Anti-Thrombotic Treatments Between Aspirin and Warfarin During Initial Six Months After Bioprpsthetic Hear · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04696042 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Asan Medical Center
- Last refreshed: 28 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04696042.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing